Mechanisms of PTH and Vitamin D Action on Kidney and Bone

Parathyroid hormone and the active vitamin D metabolite calcitriol raise serum calcium by acting on the kidney, bone, and — for calcitriol — the intestine. PTH binds the PTH/PTHrP receptor on renal tubular cells and osteoblasts, while calcitriol acts through the nuclear vitamin D receptor to regulate gene transcription. Together they coordinate renal handling of calcium and phosphate, intestinal absorption, and the remodeling of bone.

Definition

This topic describes the receptor-level and cellular mechanisms by which parathyroid hormone and calcitriol act on kidney, bone, and intestine to regulate calcium and phosphate, including PTH/PTHrP receptor signaling, the vitamin D receptor, and RANKL-driven bone remodeling.

Scope

This topic covers the cellular mechanisms by which PTH and calcitriol act on their target organs: PTH signaling through the PTH/PTHrP receptor in the renal tubule and on osteoblasts, the indirect activation of osteoclasts through the RANKL-osteoprotegerin system that drives bone remodeling, the renal effects on calcium reabsorption and phosphate excretion, and calcitriol's vitamin-D-receptor-mediated stimulation of intestinal calcium and phosphate absorption. It is a reference-educational account of normal mechanisms, not clinical guidance.

Key concepts

• PTH/PTHrP receptor (PTH1R)
• Vitamin D receptor (VDR)
• RANKL-RANK-osteoprotegerin axis
• Osteoblast-osteoclast coupling
• Bone remodeling
• Distal tubular calcium reabsorption
• Proximal tubular phosphate excretion
• Intestinal calcium and phosphate absorption

Mechanisms

PTH acts through the G-protein-coupled PTH/PTHrP receptor (PTH1R), expressed on renal tubular cells and on osteoblasts. In the kidney, PTH increases calcium reabsorption in the distal nephron, inhibits phosphate reabsorption in the proximal tubule (promoting phosphaturia), and stimulates 1-alpha-hydroxylase to make calcitriol. In bone, PTH does not act directly on osteoclasts; instead it signals through osteoblasts and stromal cells to increase expression of RANKL relative to its decoy receptor osteoprotegerin, thereby promoting osteoclast differentiation and bone resorption that releases calcium and phosphate. Calcitriol binds the nuclear vitamin D receptor, which heterodimerizes with the retinoid X receptor to regulate transcription of genes mediating intestinal calcium and phosphate absorption and contributing to bone remodeling. The net effect of the two hormones is a coordinated rise in serum calcium drawn from gut, kidney, and bone.

Clinical relevance

These mechanisms underlie the physiological interpretation of how calcium and phosphate are mobilized and conserved, and they frame concepts such as the renal phosphaturic effect of PTH and PTH-driven bone turnover. This entry describes normal mechanisms and is not a basis for diagnosis or treatment.

History

Recognition that PTH raises calcium through coordinated renal and skeletal actions developed alongside the cloning of the PTH/PTHrP receptor and the vitamin D receptor. A major conceptual advance was the discovery of the RANKL-RANK-osteoprotegerin system around the turn of the millennium, which explained how PTH and other factors regulate osteoclast formation indirectly through osteoblast-lineage cells, clarifying the cellular logic of bone remodeling.

Key figures

• Lorenz C. Hofbauer
• Sundararaman Swaminathan

Seminal works

• khundmiri-2016
• hofbauer-2000
• christakos-2016

Frequently asked questions

Does PTH act directly on osteoclasts?

No. PTH acts on osteoblasts and stromal cells, which respond by increasing RANKL relative to osteoprotegerin; this in turn drives osteoclast differentiation and the bone resorption that releases calcium.

How do PTH and calcitriol differ in their target actions?

PTH signals through a cell-surface receptor to alter renal calcium and phosphate handling and bone remodeling, while calcitriol acts through a nuclear receptor to regulate gene transcription, notably increasing intestinal calcium and phosphate absorption.